Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Civitas Therapeutics that uses the ARCUS respiratory delivery platform in developing transformative therapeutics, has announced the start of Phase 2a clinical trial in Parkinson's patients evaluating CVT-301,an inhaled formulation of levodopa (L-dopa).
Subscribe to our email newsletter
CVT-301 provides immediate onset of a large and precise dose of L-dopa.
The Phase 2a study is a randomized, placebo-controlled, single dose, cross-over design that will feature the safety and tolerability of CVT-301.
The trial also will study pharmacodynamic effects and L-dopa pharmacokinetics in patients with Parkinson’s disease with motor fluctuations.
The study will also asses the dose for future clinical trials with CVT-301. Patients will receive oral Sinemet, inhaled placebo and CVT-301 which will be followed by a series of evaluations of L-dopa pharmacokinetics, motor response and safety at each visit.
Twenty-four patients will participate in the trial.
Civitas co-founder Dr.Martin Freed said,”Consistent with our commitment to rapidly develop important new therapies for patients, we demonstrated pharmacokinetic proof-of-concept for CVT-301 in less than 12 months from launching Civitas and are now initiating this Phase 2a study in Parkinson’s patients."